1998 to 2023 Saw Decline in Triplet, Higher-Order Birth Rate
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Nov. 1, 2024 -- From 1998 to 2023, there was a decline in the triplet and higher-order birth rate, according to an October data brief published by the National Center for Health Statistics.
Joyce A. Martin, M.P.H., and Michelle J.K. Osterman, from the National Center for Health Statistics in Hyattsville, Maryland, examined changes in triplet and higher-order births from 1998 to 2023 using data from the National Vital Statistics System.
The researchers noted a decline in the triplet and higher-order multiple birth rate from 193.5 to 73.8 births per 100,000 total births from 1998 to 2023, with the largest declines from 2009 to 2023. The number of triplet and higher-order births declined from 7,625 to 2,653 from 1998 to 2023. During the study period, there were declines observed in the triplet and higher-order birth rates among White non-Hispanic and Hispanic mothers (71 and 25 percent, respectively), while an increase was seen in the rate for Black non-Hispanic mothers (25 percent). For all age groups from 20 years and older, triplet and higher-order birth rates decreased from 1998 to 2023; the largest declines were seen for mothers aged 30 years and older.
"The triplet and higher-order birth rate declined 62 percent from 1998 to 2023; the number of triplet births declined by a similar amount (64 percent), and the number of quadruplet and higher-order births declined by more than three-quarters (79 percent)," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-02 12:00
Read more
- There's a 'Sweet Spot' for Daily Sugar Intake & Heart Health
- Prior Authorization Leads to Radiation Oncology Treatment Delays, Patient Harm
- Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
- Zepbound Slashes Diabetes Risk in Obese Users
- Study Warns That Cats Might Be Bird Flu Carriers
- As 'Teletherapy' Takes Hold, Nearly 12% of Young Adults Now Undergo Psychotherapy
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions